搜索医生

Stacey A. Rizza, M.D.

  1. Infectious Disease Specialist
预约门诊

出版物

  1. Higgins E, Yuan J, Lange S, Boilson BA, Pritt BS, Rizza SA. Fever, Cough, and Pancytopenia in a Transplant Recipient. Clin Infect Dis. 2023 Oct 5; 77 (7):1065-1067
    View PubMed
  2. Zeuli JD, Rivera CG, Wright JA, Kasten MJ, Mahmood M, Ragan AK, Rizza SA, Temesgen Z, Vergidis P, Wilson JW, Cummins NW. Pharmacogenomic panel testing provides insight and enhances medication management in people with HIV. AIDS. 2023 Aug 1; 37 (10):1525-1533 Epub 2023 May 11
    View PubMed
  3. Pope ZC, Weisend CM, Shah A, Ebihara H, Rizza SA. Inactivation of replication-competent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on common surfaces by disinfectants. Infect Control Hosp Epidemiol. 2023 Mar; 44 (3):504-506 Epub 2022 Jan 26
    View PubMed
  4. Zeuli JD, Rivera CG, Wright JA, Kasten MJ, Mahmood M, Ragan AK, Rizza SA, Temesgen Z, Vergidis P, Wilson JW, Cummins NW. Pharmacogenomic panel testing provides insight and enhances medication management in people with HIV. AIDS (London, England). 2023; 37 (10):1525-33
  5. Pope ZC, Weisend CM, Shah A, Ebihara H, Rizza SA. Inactivation of replication-competent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on common surfaces by disinfectants. Infection Control and Hospital Epidemiology. 2023; 44 (3):504-6
  6. Saeed H, Cano EJ, Khan MQ, Yetmar ZA, Smith B, Rizza SA, Badley AD, Mahmood M, Leise MD, Cummins NW. Changing Landscape of Liver Transplantation in the Post-DAA and Contemporary ART Era. Life (Basel). 2022 Nov 1; 12 (11) Epub 2022 Nov 01
    View PubMed
  7. Wissler Gerdes EO, Vanichkachorn G, Verdoorn BP, Hanson GJ, Joshi AY, Murad MH, Rizza SA, Hurt RT, Tchkonia T, Kirkland JL. Role of senescence in the chronic health consequences of COVID-19. Transl Res. 2022 Mar; 241:96-108 Epub 2021 Oct 22
    View PubMed
  8. MacDonald DM, Collins G, Wendt CH, Wolfson J, Tracy RP, Rhame F, Deeks S, Rizza SA, Temesgen Z, Morse C, Liappis AP, Sereti I, Baker JV, Kunisaki KM. Short Communication: A Pilot Study of the Effects of Losartan Versus Placebo on Pneumoproteins in HIV: A Secondary Analysis of a Randomized Double Blind Study. AIDS Res Hum Retroviruses. 2022 Feb; 38 (2):127-130 Epub 2021 Apr 30
    View PubMed
  9. Cummins NW, Baker J, Chakraborty R, Dean PG, Garcia-Rivera E, Krogman A, Kumar S, Kuzmichev YV, Laird GM, Landay A, Lichterfeld M, Mahmood M, Martinson J, Maynes M, Natesampillai S, Rajkumar V, Rassadkina Y, Ritter KD, Rivera CG, Rizza SA, Subramanian K, Tande AJ, Wonderlich ER, Whitaker JA, Zeuli J, Badley AD. Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo. EClinicalMedicine. 2021 Dec; 42:101225 Epub 2021 Nov 29
    View PubMed
  10. Verdoorn BP, Evans TK, Hanson GJ, Zhu Y, Langhi Prata LGP, Pignolo RJ, Atkinson EJ, Wissler-Gerdes EO, Kuchel GA, Mannick JB, Kritchevsky SB, Khosla S, Rizza SA, Walston JD, Musi N, Lipsitz LA, Kiel DP, Yung R, LeBrasseur NK, Singh RJ, McCarthy T, Puskarich MA, Niedernhofer LJ, Robbins PD, Sorenson M, Tchkonia T, Kirkland JL. Fisetin for COVID-19 in skilled nursing facilities: Senolytic trials in the COVID era. J Am Geriatr Soc. 2021 Nov; 69 (11):3023-3033 Epub 2021 Aug 20
    View PubMed
  11. Alexander MP, Mangalaparthi KK, Madugundu AK, Moyer AM, Adam BA, Mengel M, Singh S, Herrmann SM, Rule AD, Cheek EH, Herrera Hernandez LP, Graham RP, Aleksandar D, Aubry MC, Roden AC, Hagen CE, Quinton RA, Bois MC, Lin PT, Maleszewski JJ, Cornell LD, Sethi S, Pavelko KD, Charlesworth J, Narasimhan R, Larsen CP, Rizza SA, Nasr SH, Grande JP, McKee TD, Badley AD, Pandey A, Taner T. Acute Kidney Injury in Severe COVID-19 Has Similarities to Sepsis-Associated Kidney Injury: A Multi-Omics Study. Mayo Clin Proc. 2021 Oct; 96 (10):2561-2575 Epub 2021 July 15
    View PubMed
  12. Pope ZC, Kottke TJ, Shah A, Vile RG, Rizza SA. Inactivation of Replication-Competent Vesicular Stomatitis Virus as SARS-CoV-2 Surrogate on Common Surfaces by Disinfectants. Int J Environ Res Public Health. 2021 Jul 20; 18 (14) Epub 2021 July 20
    View PubMed
  13. Koshy M, Mische L, Rizza S, Mahmood M, Bedimo R, Bhatia R, El Atrouni W, Curran J, Temesgen Z. Point-of-care program in HIV, tuberculosis, and associated conditions: A virtual global technical assistance platform to strengthen HIV and tuberculosis workforce capacity. J Clin Tuberc Other Mycobact Dis. 2021 May; 23:100238 Epub 2021 Apr 22
    View PubMed
  14. Baker JV, Wolfson J, Collins G, Morse C, Rhame F, Liappis AP, Rizza S, Temesgen Z, Mystakelis H, Deeks S, Neaton J, Schacker T, Sereti I, Tracy RP. Losartan to reduce inflammation and fibrosis endpoints in HIV disease. AIDS. 2021 Mar 15; 35 (4):575-583
    View PubMed
  15. O'Horo JC, Cerhan JR, Cahn EJ, Bauer PR, Temesgen Z, Ebbert J, Abril A, Abu Saleh OM, Assi M, Berbari EF, Bierle DM, Bosch W, Burger CD, Cano Cevallos EJ, Clements CM, Carmona Porquera EM, Castillo Almeida NE, Challener DW, Chesdachai S, Comba IY, Corsini Campioli CG, Crane SJ, Dababneh AS, Enzler MJ, Fadel HJ, Ganesh R, De Moraes AG, Go JR, Gordon JE, Gurram PR, Guru PK, Halverson EL, Harrison MF, Heaton HA, Hurt R, Kasten MJ, Lee AS, Levy ER, Libertin CR, Mallea JM, Marshall WF 3rd, Matcha G, Meehan AM, Franco PM, Morice WG 2nd, O'Brien JJ, Oeckler R, Ommen S, Oravec CP, Orenstein R, Ough NJ, Palraj R, Patel BM, Pureza VS, Pickering B, Phelan DM, Razonable RR, Rizza S, Sampathkumar P, Sanghavi DK, Sen A, Siegel JL, Singbartl K, Shah AS, Shweta F, Speicher LL, Suh G, Tabaja H Jr, Tande A, Ting HH, Tontz RC 3rd, Vaillant JJ, Vergidis P, Warsame MY, Yetmar ZA, Zomok CCD, Williams AW, Badley AD. Outcomes of COVID-19 With the Mayo Clinic Model of Care and Research. Mayo Clin Proc. 2021 Mar; 96 (3):601-618 Epub 2020 Dec 26
    View PubMed
  16. Abu Dabrh AM, Boehmer KR, Shippee N, Rizza SA, Perlman AI, Dick SR, Behnken EM, Montori VM. Minimally disruptive medicine (MDM) in clinical practice: a qualitative case study of the human immunodeficiency virus (HIV) clinic care model. BMC Health Serv Res. 2021 Jan 6; 21 (1):24 Epub 2021 Jan 06
    View PubMed
  17. Esquer Garrigos Z, Jandhyala D, Vijayvargiya P, Castillo Almeida NE, Gurram P, Corsini Campioli CG, Stulak JM, Rizza SA, O'Horo JC, DeSimone DC, Baddour LM, Sohail MR. Management of Bloodstream Infections in Left Ventricular Assist Device Recipients: To Suppress, or Not to Suppress? Open Forum Infect Dis. 2021 Jan; 8 (1):ofaa532 Epub 2020 Nov 16
    View PubMed
  18. Sangarlangkarn A, Rizza SA, Mahmood M, Cummins NW, Temesgen Z. A National Survey of Provider's Preparedness to Care for Persons Living With HIV Aged >/=50 Years. J Contin Educ Health Prof. 2021 Jan 1; 41 (1):82-84
    View PubMed
  19. Temesgen Z, Assi M, Shweta FNU, Vergidis P, Rizza SA, Bauer PR, Pickering BW, Razonable RR, Libertin CR, Burger CD, Orenstein R, Vargas HE, Palraj R, Dababneh AS, Chappell G, Chappell D, Ahmed O, Sakemura R, Durrant C, Kenderian SS, Badley AD. GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study. Mayo Clin Proc. 2020 Nov; 95 (11):2382-2394 Epub 2020 Sept 03
    View PubMed
  20. Lim S, DeBruin DA, Leider JP, Sederstrom N, Lynfield R, Baker JV, Kline S, Kesler S, Rizza S, Wu J, Sharp RR, Wolf SM. Developing an Ethics Framework for Allocating Remdesivir in the COVID-19 Pandemic. Mayo Clin Proc. 2020 Sep; 95 (9):1946-1954 Epub 2020 June 20
    View PubMed
  21. Esquer Garrigos Z, Castillo Almeida NE, Gurram P, Vijayvargiya P, Corsini Campioli CG, Stulak JM, Rizza SA, Baddour LM, Rizwan Sohail M. Management and Outcome of Left Ventricular Assist Device Infections in Patients Undergoing Cardiac Transplantation. Open Forum Infect Dis. 2020 Aug; 7 (8):ofaa303 Epub 2020 July 20
    View PubMed
  22. Wagner T, Shweta F, Murugadoss K, Awasthi S, Venkatakrishnan AJ, Bade S, Puranik A, Kang M, Pickering BW, O'Horo JC, Bauer PR, Razonable RR, Vergidis P, Temesgen Z, Rizza S, Mahmood M, Wilson WR, Challener D, Anand P, Liebers M, Doctor Z, Silvert E, Solomon H, Anand A, Barve R, Gores G, Williams AW, Morice WG 2nd, Halamka J, Badley A, Soundararajan V. Augmented curation of clinical notes from a massive EHR system reveals symptoms of impending COVID-19 diagnosis. Elife. 2020 Jul 7; 9 Epub 2020 July 07
    View PubMed
  23. Temesgen Z, Assi M, Vergidis P, Rizza SA, Bauer PR, Pickering BW, Razonable RR, Libertin CR, Burger CD, Orenstein R, Vargas HE, Varatharaj Palraj BR, Dababneh AS, Chappell G, Chappell D, Ahmed O, Sakemura R, Durrant C, Kenderian SS, Badley A. First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe COVID-19 Pneumonia. medRxiv 2020 Jun 14 Epub 2020 June 14
    View PubMed
  24. Wyman Engen N, Huppler Hullsiek K, Belloso WH, Finley E, Hudson F, Denning E, Carey C, Pearson M, Kagan J, INSIGHT START Study Group. A randomized evaluation of on-site monitoring nested in a multinational randomized trial. Clin Trials. 2020 Feb; 17 (1):3-14 Epub 2019 Oct 24
    View PubMed
  25. Ghazi L, Baker JV, Sharma S, Jain MK, Palfreeman A, Necsoi C, Murray DD, Neaton JD, Drawz PE, INSIGHT START study group. Role of Inflammatory Biomarkers in the Prevalence and Incidence of Hypertension Among HIV-Positive Participants in the START Trial. Am J Hypertens. 2020 Jan 1; 33 (1):43-52
    View PubMed
  26. Quan K, Rizza SA, Whitaker JA, Hernandez P, Davey RT Jr, Fernandez-Cruz E, Markowitz N, Pett S, Babiker AG, Wentworth D, Khurana S, Engen N, Gordin F, Jain MK, Kan V, Polizzotto MN, Riska P, Ruxrungtham K, Temesgen Z, Lundgren J, Beigel JH, Lane HC, Neaton JD, INSIGHT FLU-IVIG Study Group. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. Lancet Respir Med. 2019 Nov; 7 (11):951-963 Epub 2019 Sept 30
    View PubMed
  27. Ekenberg C, Tang MH, Zucco AG, Murray DD, MacPherson CR, Hu X, Sherman BT, Losso MH, Wood R, Paredes R, Molina JM, Helleberg M, Jina N, Kityo CM, Florence E, Polizzotto MN, Neaton JD, Lane HC, Lundgren JD, INSIGHT START study group . Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial. J Infect Dis. 2019 Sep 13; 220 (8):1325-1334
    View PubMed
  28. Arslan S, Litzow MR, Cummins NW, Rizza SA, Badley AD, Navarro W, Hashmi SK. Risks and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Patients with HIV Infection. Biol Blood Marrow Transplant. 2019 Aug; 25 (8):e260-e267 Epub 2019 Mar 26
    View PubMed
  29. Fida M, Rizza SA, Temesgen Z. Dolutegravir plus lamivudine dual therapy - a new option for initial antiretroviral therapy. Drugs Today (Barc). 2019 May; 55 (5):297-304
    View PubMed
  30. Reid E, Suneja G, Ambinder RF, Ard K, Baiocchi R, Barta SK, Carchman E, Cohen A, Crysler OV, Gupta N, Gustafson C, Hall A, Johung KL, Klopp A, LaCasce AS, Lin C, Mehta A, Menon MP, Morgan D, Nathwani N, Noy A, Ratner L, Rizza S, Rudek MA, Sanchez J, Taylor J, Tomlinson B, Wang CJ, Yendamuri S, Dwyer MA, Freedman-Cass DA, CGC. AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 Feb; 17 (2):171-189
    View PubMed
  31. Rizza SA, Bhatia R, Zeuli J, Temesgen Z. Ibalizumab for the treatment of multidrug-resistant HIV-1 infection. Drugs Today (Barc). 2019 Jan; 55 (1):25-34
    View PubMed
  32. Paim AC, Rizza SA, Badley AD, Prieto M, Taler SJ, Chong PP, Cummins NW. Transient Loss of HIV-1 DNA in an HIV-1 Positive Patient After Kidney Transplantation: A Case Report. Am J Med 2018 Oct; 131 (10):e423-e424 Epub 2018 May 03
    View PubMed
  33. Reid E, Suneja G, Ambinder RF, Ard K, Baiocchi R, Barta SK, Carchman E, Cohen A, Gupta N, Johung KL, Klopp A, LaCasce AS, Lin C, Makarova-Rusher OV, Mehta A, Menon MP, Morgan D, Nathwani N, Noy A, Palella F, Ratner L, Rizza S, Rudek MA, Taylor J, Tomlinson B, Wang CJ, Dwyer MA, Freedman-Cass DA. Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Aug; 16 (8):986-1017
    View PubMed
  34. Nehra V, Rizza SA, Temesgen Z. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection in adults. Drugs Today (Barc). 2018 Jul; 54 (7):407-421
    View PubMed
  35. Rizza SA, Bhatia R, Temesgen Z. Novel HIV drugs and drug delivery strategies. A report from the 2018 Conference on Retroviruses and Opportunistic Infections Drugs of the Future 2018. 2018; 43(4):283-288.
  36. Rizza SA, Bhatia R, Temesgen Z. Novel hiv drugs and drug delivery strategies. a report from the 2018 conference on retroviruses and opportunistic infections Boston, Msachusetts, USA - March 4-7, 2018 Drugs Of The Future. 2018 Apr; 43 (4):283-8
  37. Brewer JD, Elston DM, Vidimos AT, Rizza SA, Miller SJ. Managing sharps injuries and other occupational exposures to HIV, HBV, and HCV in the dermatology office. J Am Acad Dermatol. 2017 Nov; 77 (5):946-951.e6 Epub 2017 Aug 31
    View PubMed
  38. Cummins NW, Rizza S, Litzow MR, Hua S, Lee GQ, Einkauf K, Chun TW, Rhame F, Baker JV, Busch MP, Chomont N, Dean PG, Fromentin R, Haase AT, Hampton D, Keating SM, Lada SM, Lee TH, Natesampillai S, Richman DD, Schacker TW, Wietgrefe S, Yu XG, Yao JD, Zeuli J, Lichterfeld M, Badley AD. Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study. PLoS Med. 2017 Nov; 14 (11):e1002461 Epub 2017 Nov 28
    View PubMed
  39. Dwyer DE, Lynfield R, Losso MH, Davey RT, Cozzi-Lepri A, Wentworth D, Uyeki TM, Gordin F, Angus B, Qvist T, Emery S, Lundgren J, Neaton JD, INSIGHT Influenza Study Group. Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009-2015. Open Forum Infect Dis. 2017 Fall; 4 (4):ofx212 Epub 2017 Oct 07
    View PubMed
  40. Rizza SA, Nehra V, Temesgen Z. Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in children. Drugs Today (Barc). 2017 Aug; 53 (8):447-451
    View PubMed
  41. Rizza SA, El Atrouni W, Bhatia R, Temesgen Z. Advances in HIV therapeutics. A report from the 2017 conference on retroviruses and opportunistic infections (CROI) Drugs Of The Future. 2017 Apr; 42: (4)241-9.
  42. Nehra V, Rizza SA, Temesgen Z. Sofosbuvir/velpatasvir fixed-dose combination for the treatment of chronic hepatitis C virus infection. Drugs Today (Barc). 2017 Mar; 53 (3):177-189
    View PubMed
  43. Sampath R, Zeuli J, Rizza S, Temesgen Z. Tenofovir alafenamide fumarate for the treatment of HIV infection. Drugs Today (Barc). 2016 Nov; 52 (11):617-625
    View PubMed
  44. Marcelin JR, Tan EM, Marcelin A, Scheitel M, Ramu P, Hankey R, Keniya P, Wingo M, Rizza SA, North F, Chaudhry R. Assessment and improvement of HIV screening rates in a Midwest primary care practice using an electronic clinical decision support system: a quality improvement study. BMC Med Inform Decis Mak. 2016 Jul 4; 16:76 Epub 2016 July 04
    View PubMed
  45. Cummins NW, Badley AD, Kasten MJ, Sampath R, Temesgen Z, Whitaker JA, Wilson JW, Yao JD, Zeuli J, Rizza SA. Twenty years of human immunodeficiency virus care at the Mayo Clinic: Past, present and future. World J Virol. 2016 May 12; 5 (2):63-7
    View PubMed
  46. Cummins NW, Sainski AM, Dai H, Natesampillai S, Pang YP, Bren GD, de Araujo Correia MCM, Sampath R, Rizza SA, O'Brien D, Yao JD, Kaufmann SH, Badley AD. Prime, Shock, and Kill: Priming CD4 T Cells from HIV Patients with a BCL-2 Antagonist before HIV Reactivation Reduces HIV Reservoir Size. J Virol. 2016 Apr; 90(8):4032-4048. Epub 2016 Mar 28.
    View PubMed
  47. Rizza SA, Cummins N, Hoffman-Therry M, Temesgen Z. 23rd conference on retroviruses and opportunistic infections (CROI 2016) Boston, Massachusetts, USA - February 22-25, 2016 Drugs Of The Future. 2016 Mar; 41: (3)203-12.
  48. INSIGHT FLU005 IVIG Pilot Study Group, INSIGHT FLU005 IVIG Pilot Study Group. INSIGHT FLU005: An Anti-Influenza Virus Hyperimmune Intravenous Immunoglobulin Pilot Study. J Infect Dis. 2016 Feb 15; 213 (4):574-8 Epub 2015 Sept 15
    View PubMed
  49. Nehra V, Tan EM, Rizza SA, Temesgen Z. Ledipasvir/sofosbuvir fixed-dose combination for treatment of hepatitis C virus genotype 4 infection. Drugs Today (Barc). 2016 Feb; 52: (2)111-7.
    View PubMed
  50. Marcelin JR, Berg ML, Tan EM, Amer H, Cummins NW, Rizza SA. Is Abnormal Urine Protein/Osmolality Ratio Associated with Abnormal Renal Function in Patients Receiving Tenofovir Disoproxil Fumarate? PLoS One. 2016; 11 (2):e0149562 Epub 2016 Feb 12
    View PubMed
  51. Zeuli JD, Adie SK, Rizza SA, Temesgen Z. Asunaprevir plus daclatasvir for the treatment of chronic hepatitis C virus infection. Drugs Today (Barc). 2015 Nov; 51 (11):629-43
    View PubMed
  52. Temesgen Z, Rizza SA. Daclatasvir for the treatment of chronic hepatitis C virus infection. Drugs Today (Barc). 2015 May; 51 (5):277-88
    View PubMed
  53. Rizza SA, Temesgen Z. Developments in the treatment of HIV and chronic hepatitis C virus infections - a report from CROI 2015 Seattle, Washington, USA - February 23-26, 2015. Drugs Future. 2015 May; 40(5):323-8.
  54. Tan EM, Marcelin JR, Tande AJ, Rizza SA, Cummins NW. Fever and Cardiac Arrest in a Patient With a Left Ventricular Assist Device. Open Forum Infect Dis. 2015 Apr; 2 (2):ofv033 Epub 2015 Mar 05
    View PubMed
  55. Achhra AC, Mocroft A, Ross JM, Ryom L, Lucas GM, INSIGHT Study Group. Kidney disease in antiretroviralnaive HIV-positive adults with high CD4: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of Antiretroviral Treatment trial HIV Med.2015;16:(S1):55-63.
  56. Temesgen Z, Talwani R, Rizza SA. Sofosbuvir for the treatment of chronic hepatitis C virus infection. Drugs Today (Barc). 2014 Jun; 50: (6)421-34.
    View PubMed
  57. Cummins NW, Neuhaus J, Sainski AM, Strausbauch MA, Wettstein PJ, Lewin SR, Plana M, Rizza SA, Temesgen Z, Touloumi G, Freiberg M, Neaton J, Badley AD, INSIGHT SMART Study Group. Short communication: CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41. AIDS Res Hum Retroviruses. 2014 May; 30 (5):476-9 Epub 2014 Feb 14
    View PubMed
  58. Temesgen Z, Talwani R, Rizza SA. Dolutegravir, an HIV integrase inhibitor for the treatment of HIV infection. Drugs Today (Barc). 2014 Jan; 50 (1):7-14
    View PubMed
  59. Lynfield R, Davey R, Dwyer DE, Losso MH, Wentworth D, Cozzi-Lepri A, Herman-Lamin K, Cholewinska G, David D, Kuetter S, Ternesgen Z, Uyeki TM, Lane HC, Lundgren J, Neaton JD, INSIGHT Influenza Study Group. Outcomes of influenza A(H1N1)pdm09 virus infection: results from two international cohort studies. PLoS One. 2014; 9 (7):e101785 Epub 2014 July 08
    View PubMed
  60. Sadarangani S, Berg ML, Mauck W, Rizza S. Iatrogenic cushing syndrome secondary to ritonavir-epidural triamcinolone interaction: an illustrative case and review. Interdiscip Perspect Infect Dis. 2014; 2014:849432 Epub 2014 May 07
    View PubMed
  61. Rizza SA, Temesgen Z. 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) Boston, Massachusetts, USA - March 3-6, 2014. Drugs Future. 2014; 39(4):309-16.
  62. Cummins NW, Neuhaus J, Sainski AM, Strausbauch MA, Wettstein PJ, Lewin S, Plana M, Rizza SA, Temesgen Z, Touloumi G, Freiberg M, Neaton J, Badley AD. CD4T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41. AIDS Res Hum Retroviruses.2013;
  63. Moua T, Rizza SA, Kennedy CC. Leg weakness in a lung transplant patient. Transpl Infect Dis. 2013 Jun; 15(3):E102-6. Epub 2013 Apr 14.
    View PubMed
  64. Rizza SA, Cummins N, El Atrouni W, Badley AD, Dababneh A, Temesgen Z. Advances in the treatment of HIV and chronic hepatitis C virus infection: A report from the 20th conference on retroviruses and opportunistic infections (CROI 2013). Drugs Future. 2013; 38(5):325-33.
  65. Patel SM, Rizza SA. The porcelain bladder: schistosomiasis. Am J Med. 2012 Dec; 125: (12)1178-80.
    View PubMed
  66. Rizza SA, MacGowan RJ, Purcell DW, Branson BM, Temesgen Z. HIV screening in the health care setting: status, barriers, and potential solutions. Mayo Clin Proc. 2012 Sep; 87 (9):915-24
    View PubMed
  67. Trushin SA, Carena AA, Bren GD, Rizza SA, Dong X, Abraham RS, Badley AD. SDF-1alpha degrades whereas glycoprotein 120 upregulates Bcl-2 interacting mediator of death extralong isoform: implications for the development of T cell memory. J Immunol. 2012 Aug 15; 189 (4):1835-42 Epub 2012 July 16
    View PubMed
  68. Talwani R, Gilliam BL, Rizza SA, Nehra V, Temesgen Z. Current status of treatment for chronic hepatitis C virus infection. Drugs Today (Barc). 2012 Mar; 48(3):219-31.
    View PubMed
  69. Nehra V, Rizza SA, Talwani R, Temesgen Z. Telaprevir: looking for a sustained virologic response in hepatitis C virus infection. Drugs Today (Barc). 2011 Nov; 47 (11):829-37
    View PubMed
  70. Schnepple DJ, Shepard B, Bren GD, Cummins NW, Natesampillai S, Trushin S, Algeciras-Schimnich A, Meng XW, Sainski AM, Rizza SA, Kaufmann SH, Badley AD. Isolation of a TRAIL antagonist from the serum of HIV-infected patients. J Biol Chem. 2011 Oct 14; 286 (41):35742-35754 Epub 2011 Aug 22
    View PubMed
  71. Rizza SA, Talwani R, Nehra V, Temesgen Z. Boceprevir. Drugs Today (Barc). 2011 Oct; 47: (10)743-51.
    View PubMed
  72. Rizza SA, Challagundla KB, Natesampillai S, Bren GD, Sykora J, Walczak H, Badley AD. TRAIL dependent fratricidal killing of gp120 primed hepatocytes by HCV core expressing hepatocytes. PLoS One. 2011; 6 (11):e27171 Epub 2011 Nov 14
    View PubMed
  73. Rizza S, Talwani R, Nehra V, Temesgen Z. Beceprivir. Drugs of Today. 2011; 47(10):743-751.
  74. Elewa U, Sandri AM, Rizza SA, Fervenza FC. Treatment of HIV-associated nephropathies. Nephron Clin Pract. 2011; 118(4):c346-54; discussion c354. Epub 2011 Feb 03.
    View PubMed
  75. Rizza SA, Cummins NW, Rider DN, Saeed S, Klein MB, Badley AD. Polymorphism in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 is associated with poor viral response to interferon-based hepatitis C virus therapy in HIV/hepatitis C virus-coinfected individuals. AIDS. 2010 Nov 13; 24 (17):2639-44
    View PubMed
  76. Taylor JA, Cummins NW, Bren GD, Rizza SA, Kolbert CP, Behrens MD, Knutson KL, Kahl JC, Asmann YW, Badley AD. Casp8p41 expression in primary T cells induces a proinflammatory response. AIDS. 2010 Jun 1; 24(9):1251-8.
    View PubMed
  77. Singh VP, Bren GD, Algeciras-Schimnich A, Schnepple D, Navina S, Rizza SA, Dawra RK, Saluja AK, Chari ST, Vege SS, Badley AD. Nelfinavir/ritonavir reduces acinar injury but not inflammation during mouse caerulein pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2009 May; 296 (5):G1040-6 Epub 2009 Mar 12
    View PubMed
  78. Babu CK, Suwansrinon K, Bren GD, Badley AD, Rizza SA. HIV induces TRAIL sensitivity in hepatocytes. PLoS One. 2009; 4 (2):e4623 Epub 2009 Feb 27
    View PubMed
  79. Shepard BD, De Forni D, McNamara DR, Foli A, Rizza SA, Abraham RS, Knutson K, Wettstein PJ, Lori F, Badley AD. Beneficial effect of TRAIL on HIV burden, without detectable immune consequences. PLoS One. 2008 Aug 28; 3 (8):e3096
    View PubMed
  80. Shepard BD, Loutfy MR, Raboud J, Mandy F, Kovacs CM, Diong C, Bergeron M, Govan V, Rizza SA, Angel JB, Badley AD. Early changes in T-cell activation predict antiretroviral success in salvage therapy of HIV infection. J Acquir Immune Defic Syndr. 2008 Jun 1; 48 (2):149-55
    View PubMed
  81. Bren GD, Whitman J, Cummins N, Shepard B, Rizza SA, Trushin SA, Badley AD. Infected cell killing by HIV-1 protease promotes NF-kappaB dependent HIV-1 replication. PLoS One. 2008 May 7; 3 (5):e2112 Epub 2008 May 07
    View PubMed
  82. Nie Z, Bren GD, Rizza SA, Badley AD. HIV Protease Cleavage of Procaspase 8 is Necessary for Death of HIV-Infected Cells. Open Virol J. 2008; 2:1-7
    View PubMed
  83. Rizza SA, Badley AD. HIV protease inhibitors impact on apoptosis. Med Chem. 2008 Jan; 4 (1):75-9
    View PubMed
  84. Rizza SR, Tangalos EG, McClees MD, Strausbauch MA, Targonski PV, McKean DJ, Wettstein PJ, Badley AD. Nelfinavir monotherapy increases naive T-cell numbers in HIV-negative healthy young adults. Front Biosci. 2008 Jan 1; 13:1605-9 Epub 2008 Jan 01
    View PubMed
  85. Algeciras-Schimnich A, Belzacq-Casagrande AS, Bren GD, Nie Z, Taylor JA, Rizza SA, Brenner C, Badley AD. Analysis of HIV Protease Killing Through Caspase 8 Reveals a Novel Interaction Between Caspase 8 and Mitochondria. Open Virol J. 2007 Dec 27; 1:39-46
    View PubMed
  86. Vlahakis SR, Bren GD, Algeciras-Schimnich A, Trushin SA, Schnepple DJ, Badley AD. Flying in the face of resistance: antiviral-independent benefit of HIV protease inhibitors on T-cell survival. Clin Pharmacol Ther. 2007 Sep; 82(3):294-9. Epub 2007 Mar 14.
    View PubMed
  87. Nie Z, Bren GD, Vlahakis SR, Schimnich AA, Brenchley JM, Trushin SA, Warren S, Schnepple DJ, Kovacs CM, Loutfy MR, Douek DC, Badley AD. Human immunodeficiency virus type 1 protease cleaves procaspase 8 in vivo. J Virol. 2007 Jul; 81 (13):6947-56 Epub 2007 Apr 18
    View PubMed
  88. Vlahakis SR, Bennett SA, Whitehead SN, Badley AD. HIV protease inhibitors modulate apoptosis signaling in vitro and in vivo. Apoptosis. 2007 May; 12(5):969-77.
    View PubMed
  89. Trushin SA, Algeciras-Schimnich A, Vlahakis SR, Bren GD, Warren S, Schnepple DJ, Badley AD. Glycoprotein 120 binding to CXCR4 causes p38-dependent primary T cell death that is facilitated by, but does not require cell-associated CD4. J Immunol. 2007 Apr 15; 178 (8):4846-53
    View PubMed
  90. Temesgen Z, Cainelli F, Poeschla EM, Vlahakis SA, Vento S. Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults. Lancet Infect Dis. 2006 Aug; 6(8):496-507.
    View PubMed
  91. Vlahakis SR. Human immunodeficiency virus and hepatitis C virus co-infection. J Med Liban. 2006 Apr-Jun; 54(2):106-10.
    View PubMed
  92. Vlahakis SR, Badley AD. Influence of proteasome inhibitors on apoptosis. Curr Opin Clin Nutr Metab Care. 2006 Jan; 9 (1):42-7
    View PubMed
  93. Mueller PS, Chedid MF, Vlahakis S, Sheedy PF, Fervenza FC. Multiple pulmonary emboli in a patient with graves disease and circulating antiphospholipid antibodies. Endocrinologist. 2004 Jul-Aug; 14(4):190-4.
  94. Vlahakis SR, Villasis-Keever A, Gomez TS, Bren GD, Paya CV. Human immunodeficiency virus-induced apoptosis of human hepatocytes via CXCR4. J Infect Dis. 2003 Nov 15; 188 (10):1455-60 Epub 2003 Nov 18
    View PubMed
  95. Vlahakis SR, Villasis-Keever A, Gomez T, Vanegas M, Vlahakis N, Paya CV. G protein-coupled chemokine receptors induce both survival and apoptotic signaling pathways. J Immunol. 2002 Nov 15; 169 (10):5546-54
    View PubMed
  96. Algeciras-Schimnich A, Vlahakis SR, Villasis-Keever A, Gomez T, Heppelmann CJ, Bou G, Paya CV. CCR5 mediates Fas- and caspase-8 dependent apoptosis of both uninfected and HIV infected primary human CD4 T cells. AIDS. 2002 Jul 26; 16 (11):1467-78
    View PubMed
  97. Vlahakis SR, Steckelberg JM. Methicillin-resistant Staphylococcus aureus: a practical primer. Emerg Med. 2001 Jul; 33(7):45-6, 48-9, 53.
  98. Vlahakis SR, Algeciras-Schimnich A, Bou G, Heppelmann CJ, Villasis-Keever A, Collman RG, Paya CV. Chemokine-receptor activation by env determines the mechanism of death in HIV-infected and uninfected T lymphocytes. J Clin Invest. 2001 Jan; 107 (2):207-15
    View PubMed
  99. Erickson LD, Rizza SA, Bergert ER, Charlesworth MC, McCormick DJ, Ryan RJ. Synthetic alpha-subunit peptides stimulate testosterone production in vitro by rat Leydig cells. Endocrinology. 1990 May; 126(5):2555-60.
    View PubMed
PST-20221577